Literature DB >> 8431356

Effects of suramin on cell-cycle kinetics of MCF-7 human breast cancer cells in vitro.

J A Foekens1, A M Sieuwerts, E M Stuurman-Smeets, H A Peters, J G Klijn.   

Abstract

The polyanionic compound suramin can inhibit the proliferation of cells of various origin, including from breast cancer. We have studied the effects of suramin on cell cycle kinetics and distribution of MCF-7 human breast cancer cells in vitro. It was found that both under serum-containing and serum-free culture conditions, and in the absence or presence of oestradiol or insulin-like growth factor-1, prolonged exposure (> or = 48 h) to suramin caused an accumulation of surviving cells in the G2/M-phase of the cell cycle. At a concentration of more than 100 micrograms ml-1 suramin significantly inhibited cell proliferation. The observed effects of suramin on breast cancer cells in vitro, i.e. antiproliferative effects and accumulation of cells in the G2/M-phase of the cell cycle, may have beneficial consequences in the application of treatment strategies based on a combination of suramin with cell cycle specific drugs or radiation therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8431356      PMCID: PMC1968164          DOI: 10.1038/bjc.1993.45

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Suramin, an active nonhormonal cytotoxic drug for treatment of prostate cancer: compelling reasons for testing in patients with hormone-refractory breast cancer.

Authors:  M A Eisenberger; J A Fontana
Journal:  J Natl Cancer Inst       Date:  1992-01-01       Impact factor: 13.506

2.  Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells.

Authors:  R Kopp; A Pfeiffer
Journal:  Cancer Res       Date:  1990-10-15       Impact factor: 12.701

3.  Suramin affects DNA synthesis in HeLa cells by inhibition of DNA polymerases.

Authors:  H K Jindal; C W Anderson; R G Davis; J K Vishwanatha
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 12.701

4.  Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells.

Authors:  M Pollak; M Richard
Journal:  J Natl Cancer Inst       Date:  1990-08-15       Impact factor: 13.506

5.  Epidermal growth factor receptor expression and suramin cytotoxicity in vitro.

Authors:  S Olivier; P Formento; J L Fischel; M C Etienne; G Milano
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

6.  Antiproliferative effects of suramin on androgen responsive tumour cells.

Authors:  E M Berns; A L Schuurmans; J Bolt; D J Lamb; J A Foekens; E Mulder
Journal:  Eur J Cancer       Date:  1990-04       Impact factor: 9.162

Review 7.  Suramin, a novel antitumor compound.

Authors:  R V La Rocca; C A Stein; R Danesi; C E Myers
Journal:  J Steroid Biochem Mol Biol       Date:  1990-12-20       Impact factor: 4.292

Review 8.  Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: preclinical and clinical studies.

Authors:  J G Klijn; B Setyono-Han; G H Bakker; M E van der Burg; M Bontenbal; H A Peters; A M Sieuwerts; P M Berns; J A Foekens
Journal:  J Steroid Biochem Mol Biol       Date:  1990-12-20       Impact factor: 4.292

9.  Effect of suramin on human prostate cancer cells in vitro.

Authors:  R V La Rocca; R Danesi; M R Cooper; C A Jamis-Dow; M W Ewing; W M Linehan; C E Myers
Journal:  J Urol       Date:  1991-02       Impact factor: 7.450

10.  Effect of hormonal manipulation and doxorubicin administration on cell cycle kinetics of human breast cancer cells.

Authors:  M Bontenbal; A M Sieuwerts; J G Klijn; H A Peters; H L Krijnen; P Sonneveld; J A Foekens
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

View more
  1 in total

1.  Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.

Authors:  M A Villalona-Calero; G A Otterson; M G Wientjes; F Weber; T Bekaii-Saab; D Young; A J Murgo; R Jensen; T-K Yeh; Y Wei; Y Zhang; C Eng; M Grever; J L-S Au
Journal:  Ann Oncol       Date:  2008-07-15       Impact factor: 32.976

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.